News PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer PARIS, FRANCE, June 23, 2022 – PathoQuest, a leading Contract Research Organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS)...
News Meet Haifa Sghairi our new NGS specialist! Mrs. Haifa Sghairi has over 10 years of experience in high-throughput sequencing services (next-generation sequencing – NGS). Prior to joining PathoQuest, Haifa was NGS Sales Manager at Novogene Europe, a Global company...
News PathoQuest Appoints Guillaume Deplaine, Ph.D., as Head of Operations Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE...
News PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer Dr. Sébastien Renouf has almost 20 years of experience in Regulatory Affairs, Risk Management, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining...
Interview with Colette Côté, Ph.D. : Chief Portfolio Officer and General Manager of PathoQuest’s U.S. subsidiary located in Wayne, PA. Return to the news page PathoQuest is a pioneer in the development and application of novel Next Generation Sequencing (NGS)-based...
Preferred Events 4th Annual NGS Seminar – 2021 Digital Edition 14 September, 2021 16:00-19:00 CST | 10:00 AM-01:00 PM EST | 07:00-10:00 AM PST The impact of COVID-19 has highlighted the biopharmaceutical industry’s need for fast & innovative solutions...
